Researchers from Charité – Universitätsmedizin Berlin report that steatotic liver disease subtypes often shift over time, with 36% of MetALD patients reclassified within six months, suggesting a need for dynamic disease monitoring.
Hair drug test positivity among US workers rose to 19.1% in 2025, a 46% increase since 2021, with marijuana accounting for over half of positive results, according to the 2026 Quest Diagnostics Drug Testing Index.
A new NIH-funded study finds that elevated circular RNAs in blood may predict Alzheimer’s symptoms years in advance, outperforming current blood tests in forecasting disease progression.
Spotlight Medical’s myStage Dx AI breast cancer test has received CE marking under EU IVDR, enabling adoption in European oncology and pathology labs for recurrence risk assessment in ER+/HER2- early breast cancer patients.
The fully automated, high-throughput assay for Hepatitis D virus RNA is available on cobas 5800/6800/8800 systems in CE mark-accepting countries.
The expanded commercialization agreement aims to increase availability of the GlycoKnow Ovarian laboratory-developed test through Aranscia's clinical workflow and technology platforms.
As autoimmune and allergy test volumes rise, labs are prioritizing workflow standardization and structured testing pathways to ensure reliable results, according to Santhosh Nair, president of immunodiagnostics at Thermo Fisher Scientific.
The assay measures lipoprotein(a) levels in molar units to improve cardiovascular risk assessment and standardization across laboratories.
Presentations will evaluate the performance of the company's pTau217 and pTau181 assays while also highlighting phase 3 clinical research for the investigational therapy trontinemab for Alzheimer's disease.
A two-year real-world study of Renalytix’s FDA-approved KidneyIntelX.dkd test showed improved kidney function and targeted treatment in 2,470 patients with type 2 diabetes.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.